Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Literature DB >> 21740359

Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Balveen Kaur¹, E Antonio Chiocca, Timothy P Cripe.

Abstract

Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.

Entities: Chemical Disease Gene Species

Mesh：

Year: 2012 PMID： 21740359 PMCID： PMC4233127 DOI： 10.2174/138920112800958814

Source DB: PubMed Journal: Curr Pharm Biotechnol ISSN： 1389-2010 Impact factor: 2.837

110 in total

1. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer.

Authors: H Kasuya; Y Nishiyama; S Nomoto; J Hosono; S Takeda; A Nakao
Journal: J Surg Oncol Date: 1999-11 Impact factor: 3.454

2. Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors: Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal: Mol Ther Date: 2008-10-28 Impact factor: 11.454

3. Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis.

Authors: Cristina P Marques; Maxim C-J Cheeran; Joseph M Palmquist; Shuxian Hu; James R Lokensgard
Journal: J Neurovirol Date: 2008-05 Impact factor: 2.643

4. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Authors: Mark A Currier; Rebecca A Gillespie; Nancy M Sawtell; Yonatan Y Mahller; Greg Stroup; Margaret H Collins; Hirokazu Kambara; E Antonio Chiocca; Timothy P Cripe
Journal: Mol Ther Date: 2008-03-25 Impact factor: 11.454

5. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors: Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal: Mol Ther Date: 2008-04-01 Impact factor: 11.454

6. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.

Authors: J Conner; L Braidwood; S M Brown
Journal: Gene Ther Date: 2008-08-14 Impact factor: 5.250

Review 7. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.

Authors: Akihiro Nawa; ChenHong Luo; Lumin Zhang; Yoko Ushjima; Daisuke Ishida; Maki Kamakura; Yasushi Fujimoto; Fumi Goshima; Fumitaka Kikkawa; Yukihiro Nishiyama
Journal: Curr Gene Ther Date: 2008-06 Impact factor: 4.391

8. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.

Authors: Alastair T M Mace; Ian Ganly; David S Soutar; S Moira Brown
Journal: Head Neck Date: 2008-08 Impact factor: 3.147

9. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.

Authors: Shanthi Ganesh; Melissa Gonzalez-Edick; Douglas Gibbons; Melinda Van Roey; Karin Jooss
Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531

10. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.

Authors: M Aghi; T Visted; R A Depinho; E A Chiocca
Journal: Oncogene Date: 2008-03-17 Impact factor: 9.867

37 in total

1. Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

Authors: Alena Cristina Jaime-Ramirez; Nina Dmitrieva; Ji Young Yoo; Yeshavanth Banasavadi-Siddegowda; Jianying Zhang; Theresa Relation; Chelsea Bolyard; Jeffrey Wojton; Balveen Kaur
Journal: J Gene Med Date: 2017-03 Impact factor: 4.565

2. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.

Authors: Tae Jin Lee; Mitra Nair; Yeshavanth Banasavadi-Siddegowda; Joseph Liu; Tejaswini Nallanagulagari; Alena Cristina Jaime-Ramirez; Jeffrey Yunhua Guo; Haroon Quadri; Jianying Zhang; Kurt H Bockhorst; Manish K Aghi; W Shawn Carbonell; Balveen Kaur; Ji Young Yoo
Journal: Mol Cancer Ther Date: 2019-03-29 Impact factor: 6.261

3. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Authors: Paolo A Ascierto; Sanjiv S Agarwala; Gennaro Ciliberto; Sandra Demaria; Reinhard Dummer; Connie P M Duong; Soldano Ferrone; Silvia C Formenti; Claus Garbe; Ruth Halaban; Samir Khleif; Jason J Luke; Lluis M Mir; Willem W Overwijk; Michael Postow; Igor Puzanov; Paul Sondel; Janis M Taube; Per Thor Straten; David F Stroncek; Jennifer A Wargo; Hassane Zarour; Magdalena Thurin
Journal: J Transl Med Date: 2017-11-16 Impact factor: 5.531

4. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.

Authors: Chelsea Bolyard; W Hans Meisen; Yeshavanth Banasavadi-Siddegowda; Jayson Hardcastle; Ji Young Yoo; Eric S Wohleb; Jeffrey Wojton; Jun-Ge Yu; Samuel Dubin; Maninder Khosla; Bo Xu; Jonathan Smith; Christopher Alvarez-Breckenridge; Pete Pow-Anpongkul; Flavia Pichiorri; Jianying Zhang; Matthew Old; Dan Zhu; Erwin G Van Meir; Jonathan P Godbout; Michael A Caligiuri; Jianhua Yu; Balveen Kaur
Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531

5. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Authors: Timothy P Cripe; Minhtran C Ngo; James I Geller; Chrystal U Louis; Mark A Currier; John M Racadio; Alexander J Towbin; Cliona M Rooney; Adina Pelusio; Anne Moon; Tae-Ho Hwang; James M Burke; John C Bell; David H Kirn; Caroline J Breitbach
Journal: Mol Ther Date: 2014-12-22 Impact factor: 11.454

6. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.

Authors: Jordi Martinez-Quintanilla; Derek He; Hiroaki Wakimoto; Ramon Alemany; Khalid Shah
Journal: Mol Ther Date: 2014-10-29 Impact factor: 11.454

7. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Authors: Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur
Journal: Clin Cancer Res Date: 2012-07-02 Impact factor: 12.531